UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION
OF LATE FILING
Commission File Number: 001-39921
|
|
|
|
|
(Check one):
|
|
☐ Form 10-K
☐ Form 20-F ☐ Form 11-K
☒ Form 10-Q
☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR
|
|
|
|
|
|
|
For Period Ended: September 30, 2021
|
|
|
|
|
|
|
☐ Transition Report on Form 10-K
|
|
|
|
|
|
|
☐ Transition Report on Form 20-F
|
|
|
|
|
|
|
☐ Transition Report on Form 11-K
|
|
|
|
|
|
|
☐ Transition Report on Form 10-Q
|
|
|
|
|
|
|
☐ Transition Report on Form N-SAR
|
|
|
|
|
|
|
For the Transition Period Ended:
|
PART I — REGISTRANT INFORMATION
SCP & CO Healthcare Acquisition Company
(Full Name of Registrant)
(Former
Name if Applicable)
2909 W Bay to Bay Blvd., Suite 300
Address of Principal Executive Office
Tampa, FL 33629
City, State
and Zip Code
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
|
|
|
|
|
|
|
☒
|
|
(a)
|
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
☒
|
|
(b)
|
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition
report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date;
and
|
|
☐
|
|
(c)
|
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition
report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)
SCP & CO Healthcare Acquisition
Company (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021 (the
“Q3 2021 Form 10-Q”) by the prescribed due date, for the reasons described below.
In connection with
the preparation of the Company’s financial statements as of September 30, 2021, management, in consultation with its advisors, identified an error made in certain of its previously issued financial statements,
arising from the manner in which, as of the closing of the Company’s initial public offering, the Company valued its Class A common stock subject to possible redemption. The Company previously determined
the value of such Class A common stock to be equal to the redemption value of such shares, after taking into consideration the terms of the Company’s Amended and Restated Certificate of Incorporation, under which a redemption
cannot result in net tangible assets being less than $5,000,001. Management has now determined, after consultation with its advisors, that the shares of Class A common stock underlying the units issued during
the initial public offering can be redeemed or become redeemable subject to the occurrence of future events considered to be outside the Company’s control. Therefore, management has concluded that the
redemption value of its Class A common stock subject to possible redemption should reflect the possible redemption of all Class A common stock. As a result, management has noted a reclassification error related to temporary equity and
permanent equity and intends to reflect any reclassification of equity for the Company’s previous audited balance sheet for the period ended January 26, 2021 and its unaudited financial statements for the periods ended March 31, 2021
and June 30, 2021 (the “Affected Periods”) in its forthcoming Q3 2021 Form 10-Q. Any such adjustments to the financial statement items for the Affected Periods will be set forth through expanded
disclosure in the financial statements included in the Q3 2021 Form 10-Q, including further describing the correction and its impact on previously reported amounts.
The Company, in consultation with its advisors, is continuing to finalize its Q3 2021 Form 10-Q financial statements
to reflect the foregoing. The Company is working diligently to complete its Q3 2021 Form 10-Q as soon as possible, and expects to file such report on or before the fifth calendar day following the
prescribed due date (or, if such date is not an EDGAR filing date, then the first EDGAR filing date thereafter).
PART IV — OTHER
INFORMATION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
|
|
Name and telephone number of person to contact in regard to this notification
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Scott Feuer
|
|
|
|
(813)
|
|
|
|
318-9600
|
|
|
|
|
|
(Name)
|
|
|
|
(Area Code)
|
|
|
|
(Telephone Number)
|
|
|
|
|
|
(2)
|
|
|
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)
|
|
|
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or
portion thereof? Yes ☐ No ☒
|
|
|
|
|
|
|
|
|
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
SCP & CO Healthcare Acquisition Company.
(Name of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: November 15, 2021
|
|
|
|
By:
|
|
/s/ Scott Feuer
|
|
|
|
|
|
|
|
Scott Feuer
|
|
|
|
|
|
|
|
Chief Executive Officer
|